XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Research And Development Cost $ 355,905 $ 185,653  
Cash 2,696,107   $ 1,182,412
Allowance for doubtful accounts 191   0
Revenues from sale of treatability services 8,000   63,501
Revenues from sales $ 793,458   $ 2,952,020
Warrants [Member]      
Antidilutive Excluded from Computation of Earnings Per Share, Amount 13,025,000   1,250,000